UroTeragLATAM

𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗣𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗖𝗮𝗻𝗰𝗲𝗿 𝗱𝘂𝗿𝗶𝗻𝗴 𝗥𝗮𝗱𝗶𝘂𝗺-𝟮𝟮𝟯 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗨𝘀𝗶𝗻𝗴 𝗣𝗦𝗠𝗔-𝗣𝗘𝗧/𝗖𝗧 𝙆𝙚𝙮 𝙄𝙣𝙨𝙞𝙜𝙝𝙩: PSMA-PET/CT performed after 3 cycles of Radium-223 therapy is prognostic for overall survival. Pairs of baseline and post-therapy PSMA-PET/CT scans, interpreted according to RECIP 1.0 and PPP criteria, were associated with overall survival (C-index: 0.66 vs. 0.63). 𝘾𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙄𝙢𝙥𝙡𝙚𝙢𝙚𝙣𝙩𝙖𝙩𝙞𝙤𝙣: PSMA-PET/CT imaging can effectively evaluate treatment response in patients with metastatic castration-resistant prostate cancer undergoing Radium-223. Interpretation of PSMA-PET/CT images using RECIP 1.0 demonstrated better performance compared to PPP criteria. 𝘿𝙞𝙨𝙘𝙤𝙫𝙚𝙧 𝙢𝙤𝙧𝙚 𝙞𝙣 𝙩𝙝𝙚 𝙛𝙪𝙡𝙡 𝙖𝙧𝙩𝙞𝙘𝙡𝙚: https://lnkd.in/ewAD-uY6 Qaid Shagera, MD, PhD | Carlos Artigas #PSMA #RECIP

primaryscore.com is a free online educational website designed to teach how to optimally use the PRIMARY score for when PSMA-PET/CT is used in the diagnosis of prostate cancer. Sign up and take the online quiz, watch the podcast explanations of both the PRIMARY score, prostate MRI reporting and prostate anatomy and an online MDT session of difficult cases. Website developed by A/Prof Narjess Ayati, supported by St Vincent's Hospital Sydney, Australia and St Vincent's Curran Foundation.

ICPO Foundation-International Centers for Precision Oncology Theranostics Virtual Summit 2024!! Odile JAUME Agolti Mariela Richard P. Baum Danny Mena Cortes Cecilia Carreras Velázquez

PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer out on The Lancet https://lnkd.in/dCH9xJPb In a phase 3 trial, [177Lu]Lu-PSMA-617 significantly improved radiographic progression-free survival compared to a change in androgen receptor pathway inhibitors (ARPI) in taxane-naive patients with PSMA-positive metastatic castration-resistant #ProstateCancer . With a median follow-up of 24.1 months, the 177Lu-PSMA-617 group had a median progression-free survival of 11.6 months versus 5.6 months in the ARPI change group. The safety profile of 177Lu-PSMA-617 was favorable, showing fewer severe adverse events compared to the ARPI change group. These results suggest that 177Lu-PSMA-617 could be an effective treatment alternative for patients who have progressed on prior ARPI therapy. Daniel Castellano Ken Herrmann Johann de Bono Neal Shore Michael Crosby Josep M Piulats Flechon Aude Mahammedi Hakim Guilhem Roubaud Prof. Dr. med. James Nagarajah Begoña Mellado González Euloge Kpamegan Samson Ghebremariam Teri Kreisl Dr. med. Celine Wilke Oliver Sartor @Karim Fizazi

A wam welcome to Lugano Switzerland for: 🔬 #APCCC25 Diagnostics: 27-28 February 2025 REGISTER AT: www.apccc.org Mark your Calendar!! We look forward to continuing crucial #ProstateCancer conversations in Lugano🇨🇭 Ken Herrmann Stefano Fanti Silke Gillessen & Aurelius Omlin

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer out on The Lancet Oncology https://lnkd.in/d-ABXvRe This multicentre retrospective study aimed to compare the prognostic value of PSMA-PET using the PROMISE (PPP) stage against established clinical nomograms for prostate cancer, focusing on overall survival. Data from 2,414 patients with #ProstateCancer from hospitals in Germany🇩🇪 were analyzed, with follow-up data linked to mortality records. Using Cox regression models, the researchers developed quantitative and visual PPP nomograms, which were validated both internally and externally The PPP nomograms showed superior or comparable predictive accuracy for overall survival compared to traditional risk scores, like STARCAP, EAU, and NCCN, in different stages of prostate cancer. Further validation and refinement are ongoing. Viktor Grünwald Lale Umutlu Jens Kleesiek Tugce Telli Anika Husing Claudia Kesch Ken Herrmann Matthias Eiber Prof. Dr. med. Kambiz Rahbar Boris Hadaschik

¹⁷⁷Lu-PSMA (R)evolution in cancer care: Is it really happening? https://ow.ly/MafX50SWGhG #RPTherapy #Cancer #NuclearMedicine

Clarity receives FDA Fast Track Designation for its diagnostic 64Cu-SAR-bisPSMA product. This designation, which is designed to expedite the development and regulatory review of novel drugs addressing serious conditions with significant unmet medical needs, provides a number of benefits in the development of 64Cu-SAR-bisPSMA, potentially reducing the New Drug Application (NDA) review time, allowing more frequent meetings with the FDA during development, and allowing Rolling Review of the planned NDA.   The Fast Track Designation is supported by the initial clinical evidence suggesting that 64Cu-SAR-bisPSMA may offer improved lesion detection compared to existing prostate cancer diagnostics. It comes at a time when Clarity is actively recruiting into its first registrational Phase III trial, CLARIFY, and preparing for an End of Phase meeting with the FDA for a second pivotal Phase III trial with 64Cu-SAR-bisPSMA.   Clarity is committed to advancing the development of this product to address the critical need for more accurate and accessible diagnostic tools in prostate cancer management. #biotech #radiopharmaceuticals #PSMA